Danger signals and inflammaging in osteoarthritis (Équipe Berenbaum)

18 - Octobre - 2019

Marion Millerand, Francis Berenbaum, Claire Jacques

Clin Exp Rheumatol. 2019;37 Suppl 120(5):48-56

Osteoarthritis (OA) is the most com- mon age-related chronic and disabling joint disease. Long considered to be a “wear and tear” disease, OA is now seen as a low-grade inflammation dis- ease that affects all tissues of the joint, involving cartilage degradation, bone remodelling, osteophytes, and synovi- tis. The process, called inflammaging, is characterised by the association of low-grade inflammation, profound changes in intra-cellular mechanisms, and the decreased efficiency of the im- mune system with ageing. The activation of innate immunity plays a critical role in the development and progression of OA. Innate immunity, including inflam- masome activation, is triggered by small endogenous molecules called alarmins or damage-associated molecular pat- terns (DAMPs). These molecules are released in the extracellular media after cell stress or damage, bind to pathogen- recognition receptors (PRRs), such as Toll-like receptors (TLRs) and the re- ceptor for advanced glycation end prod- ucts (RAGE), and activate the secretion of pro-inflammatory factors, leading to joint inflammation. Moreover, such sterile inflammation triggers cell senes- cence, characterised by a senescence- associated secretory phenotype (SASP). Understanding the substantial age-re- lated changes of joint tissues that influ- ence the pathogenesis of OA is critical to improving the quality of life of elderly people in the context of increased life expectancy. This review will focus on age-related sterile inflammation in OA and highlight the various innovative and promising therapies targeting the mechanisms of aging.

Hôpital St-Antoine

Bâtiment Kourilsky
34 rue Crozatier
75012 PARIS

Sorbonne Université
27 rue Chaligny
75012 PARIS

Ce site utilise des cookies et vous donne le contrôle sur ce que vous souhaitez activer Tout accepter Personnaliser